(ATXI) – Company Press Releases
-
Avenue Therapeutics Announces Reverse Stock Split
-
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
-
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
-
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
-
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
-
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
-
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
-
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
-
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
-
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
-
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
-
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
-
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
-
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
-
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
-
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
-
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
-
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
-
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
-
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
-
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
-
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
-
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulba
-
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
-
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
-
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
-
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
-
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
-
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
-
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
-
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
-
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
-
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
-
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
-
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
-
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
-
Avenue Therapeutics Stock Trading Halted Today
-
Avenue Therapeutics Stock Trading Halted Today
-
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
-
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
-
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
Back to ATXI Stock Lookup
